Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 HYPR | Healthcare | $0.63 | 774.64K | $75.54M | -2.25 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| HYPR | Hyperfine | 0.63 | -0.44 | -40.96% |
| Name | Price | % Change | |
|---|---|---|---|
| HYPR | $0.63 | -40.96% |
Hyperfine Inc. ($HYPR) announced an update on their ongoing clinical study. Study Overview: Hyperfine’s study, officially titled Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems, examines whether
Hyperfine Inc. (($HYPR)) has held its Q3 earnings call. Read on for the main highlights of the call. Hyperfine reported a strongly positive third quarter, marked by record revenue, gross
Reports Q3 revenue $6.0M, consensus $5.9M. “Q3 2026 marked the beginning of a new trajectory for Hyperfine (HYPR). We delivered record revenue, gross profit, and gross margin, and for the
Management continues to expect net cash burn1 for the full year 2026 to be approximately $26 to $28 million, representing a 10% decline at the midpoint as compared to full
17:16 EST Hyperfine (HYPR) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended
Hyperfine Inc. (HYPR) is scheduled to report 3rd quarter earnings on 11/09/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Hyperfine Inc. to post earnings of -$0.08
Meetings to be held on the West Coast on November 11-13 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try
Lucid Capital analyst Alex Nowak initiated coverage of Hyperfine (HYPR) with a Buy rating and $2 price target The company’s Swoop system is the first and only commercially available FDA-cleared
Hyperfine (HYPR) announced CE mark and UKCA approval for its latest Optive AI software update in Europe, further enhancing the capabilities of the Swoop system and supporting broader adoption across
Hyperfine ( ($HYPR) ) just unveiled an update. On October 8, 2026, Hyperfine reported preliminary third-quarter 2026 revenue of about $6.0 million, a record for the company and a 53%
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| HYPR | Mar 24, 2027TBA | $75.54M | $-0.08 | $6.74M | 0.10 | -2.25 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
